Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06548802
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-07
Brief Title:
Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary Injury
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BRIGHT
Brief Summary:
Some patients with intracerebral hemorrhage will develop severe lung injury such as respiratory distress syndrome Baricitinib has been approved by the FDA for severe pneumonia caused by the coronavirus and has been used in the treatment of hospitalized patients with COVID-19 Baricitinib significantly reduced the risk of death and shortened the length of stay in COVID-19 patients According to clinical observations there was no significant increase in deaths or infections due to non-COVID-19 causes during recovery nor was there a significant increase in thrombosis Excessive inflammatory factors release can cause inflammatory storms that damage lung cells lead to lung injury and eventually lead to respiratory failure respiratory distress syndrome and other conditions endangering life safety Studies have shown that Baricitinib can inhibit the production of excessive pro-inflammatory cytokines by lung macrophages through the JAK pathway and reduce lung injury caused by inflammatory storms Therefore in patients with acute stroke with lung infection or severe lung injury short-term use of baricitinib will help to reduce lung injury and promote the recovery of neurological function and shorten the length of hospital stay However there is currently a lack of effective clinical evidence of baricitinib in the treatment of lung injury after intracerebral hemorrhage and further research is needed
Detailed Description:
The objective of this study was to evaluate the efficacy and safety of baricitinib in patients with pulmonary injury after intracerebral hemorrhage
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None